- In June 2023, AstraZeneca partnered exclusively with Quell Therapeutics to advance engineered T-regulatory (Treg) cell therapies. The collaboration focuses on developing ground breaking treatments for Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). By leveraging Quell's Treg cell engineering expertise and AstraZeneca's drug development capabilities, this alliance could pioneer curative solutions for autoimmune disorders. It marks a shift from symptom management to potential long-term remission or cures. This advancement is poised to reshape the autoimmune disease treatment market, reduce healthcare costs, and inspire further investment in cell-based therapies, reflecting a transformative era in tackling chronic autoimmune conditions
- In January 2023, Penn Medicine researchers explored chimeric antigen receptor (CAR) T cell therapy, a breakthrough typically used in cancer treatment, for myasthenia gravis (MG), a rare autoimmune disorder. This pioneering approach offers promise for personalized and potentially transformative solutions to MG, marking a significant milestone in autoimmune disease therapy. The application of CAR T cell therapy in MG highlights the potential of advanced, targeted treatments for autoimmune conditions. This innovation could shift the market focus toward curative approaches, reduce chronic treatment costs, and drive investment in personalized therapies, signaling a new era in managing autoimmune diseases
- In May 2022, Nuvig Therapeutics, Inc. was founded with a mission to develop immune-modulating therapies aimed at managing autoimmune diseases while maintaining normal immune function. The company successfully raised USD 47 million in Series A funding, showcasing strong investor confidence in its pioneering approach to autoimmune disease treatment. Nuvig's innovative focus on immune modulation could redefine the market by offering safer, more effective therapies that address the root causes of autoimmune disorders. This approach may reduce reliance on broad immunosuppressants, driving advancements in precision medicine and attracting further investment, ultimately transforming the treatment landscape for autoimmune diseases
- In June 2022, Roivant Sciences and Pfizer joined forces to establish Priovant Therapeutics, a company dedicated to developing and commercializing innovative therapies for autoimmune diseases with significant morbidity and mortality. This partnership highlights the shared commitment of both organizations to addressing critical unmet medical needs in the autoimmune disease treatment space. Priovant Therapeutics' focus on high-impact autoimmune conditions could drive advancements in targeted therapies, offering more effective solutions for patients. This collaboration reflects a growing trend toward innovation in autoimmune treatments, potentially reshaping the market by addressing severe conditions and attracting further investment in cutting-edge therapeutic approaches
- In February 2022, Revolo Biotherapeutics secured approval from the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate two Phase II trials for its autoimmune disease drug candidate "1805." This authorization marks a crucial milestone, advancing the clinical evaluation of a promising treatment for autoimmune disorders. The regulatory approval for "1805" reflects progress in innovative drug development for autoimmune diseases, emphasizing targeted and effective solutions. Phase II trials signal growing confidence in Revolo's approach, attracting attention from investors and researchers. Success could redefine treatment options, inspire further advancements, and strengthen the market's focus on new therapies
Frequently Asked Questions
Companies such as Autoimmune Inc (U.S.), Siemens Healthcare Private Limited (Germany), LUPIN. (India), Thermo Fisher Scientific Inc (U.S.), Beckman Coulter, Inc (U.S.), are the major companies in the autoimmune disease treatment market.
The countries covered in the autoimmune disease treatment market are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Austria, Poland, Norway, Ireland, Hungary, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia, Singapore, rest of Asia-Pacific, Brazil, Argentina, Chili, Colombia, Peru, Venezuela, Ecuador, Uruguay, Paraguay ,Bolivia, Trinidad And Tobago, Curaçao, rest Of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, rest of Middle East and Africa, Guatemala, Costa Rica, Honduras, EL Salvador, Nicaragua, and rest of Central America.
